{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:12:04Z","timestamp":1784045524382,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100019595","name":"Youth and Middle-aged Scientific and Technological Innovation Leading Talents Program of the Corps","doi-asserted-by":"publisher","award":["Q20250098"],"award-info":[{"award-number":["Q20250098"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100019595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mater Sci: Mater Med"],"DOI":"10.1007\/s10856-026-07074-7","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:43:02Z","timestamp":1779356582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineered membrane-coated nanoparticles enhance ferroptosis and microtubule inhibition in prostate cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Kunmu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"7074_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10:2019.","journal-title":"World J Oncol"},{"key":"7074_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, Soerjomataram I, Briganti A, Dahut W, et al. Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol. 2025;87:302\u201313.","journal-title":"Eur Urol"},{"key":"7074_CR3","doi-asserted-by":"crossref","unstructured":"De Luca R, Gouyou B, Ongaro T, Villa A, Ziffels B, Sannino A, et al.: A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas. 2019, Volume 9 - 2019.","DOI":"10.3389\/fonc.2019.01228"},{"key":"7074_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/or.2025.8879","volume":"53","author":"X Guo","year":"2025","unstructured":"Guo X, Li S. Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review). Oncol Rep. 2025;53:46.","journal-title":"Oncol Rep"},{"key":"7074_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22:24\u201338.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7074_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"7074_CR7","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013;32:5501\u201311.","journal-title":"Oncogene"},{"key":"7074_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1623181","volume":"2022","author":"L Huang","year":"2022","unstructured":"Huang L, Peng Y, Tao X, Ding X, Li R, Jiang Y, et al. Microtubule organization is essential for maintaining cellular morphology and function. Oxid Med Cell Longev. 2022;2022:1623181.","journal-title":"Oxid Med Cell Longev"},{"key":"7074_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188607","volume":"1876","author":"A Kanakkanthara","year":"2021","unstructured":"Kanakkanthara A, Miller JH. \u03b2III-tubulin overexpression in cancer: Causes, consequences, and potential therapies. Biochimica et Biophysica Acta (BBA) - Rev Cancer. 2021;1876:188607.","journal-title":"Biochimica et Biophysica Acta (BBA) - Rev Cancer"},{"key":"7074_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.bjc.6605489","volume":"102","author":"C Stengel","year":"2010","unstructured":"Stengel C, Newman SP, Leese MP, Potter BVL, Reed MJ, Purohit A. Class III \u03b2-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer. 2010;102:316\u201324.","journal-title":"Br J Cancer"},{"key":"7074_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2165\/11591390-000000000-00000","volume":"71","author":"C Villanueva","year":"2011","unstructured":"Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, et al. Cabazitaxel. Drugs. 2011;71:1251\u20138.","journal-title":"Drugs"},{"key":"7074_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.","journal-title":"Lancet"},{"key":"7074_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-025-00656-1","volume":"14","author":"J Venturini","year":"2025","unstructured":"Venturini J, Chakraborty A, Baysal MA, Tsimberidou AM. Developments in nanotechnology approaches for the treatment of solid tumors. Exp Hematol Oncol. 2025;14:76.","journal-title":"Exp Hematol Oncol"},{"key":"7074_CR14","doi-asserted-by":"publisher","first-page":"115328","DOI":"10.1016\/j.biopha.2023.115328","volume":"166","author":"M Ghasemian","year":"2023","unstructured":"Ghasemian M, Kazeminava F, Naseri A, Mohebzadeh S, Abbaszadeh M, Kafil HS, et al. Recent progress in tannic acid based approaches as a natural polyphenolic biomaterial for cancer therapy: A review. Biomed Pharmacother. 2023;166:115328.","journal-title":"Biomed Pharmacother"},{"key":"7074_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2025.216980","volume":"544","author":"AR Aleem","year":"2025","unstructured":"Aleem AR, Ali W, Pan H, Xia C, Liu C, Yan Z, et al. Multifunctional peptide- and natural polymer-based smart biomaterials: Synthetic approaches and cancer treatment applications. Coord Chem Rev. 2025;544:216980.","journal-title":"Coord Chem Rev"},{"key":"7074_CR16","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1039\/D2TB01056A","volume":"10","author":"H Jafari","year":"2022","unstructured":"Jafari H, Ghaffari-Bohlouli P, Niknezhad SV, Abedi A, Izadifar Z, Mohammadinejad R, et al. Tannic acid: a versatile polyphenol for design of biomedical hydrogels. J Mater Chem B. 2022;10:5873\u2013912.","journal-title":"J Mater Chem B"},{"key":"7074_CR17","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1007\/s40843-024-3139-3","volume":"67","author":"H Luo","year":"2024","unstructured":"Luo H, Xie J, Su X, Wang P, Chen H, Kuang X, et al. Tannic acid-based metal-phenolic networks as a versatile platform to mediate cell therapy. Sci China Mater. 2024;67:3833\u201348.","journal-title":"Sci China Mater"},{"key":"7074_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202003492","volume":"32","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Pan DC, Qi QM, Kim J, Kapate N, Sun T, et al. Engineering of living cells with polyphenol-functionalized biologically active nanocomplexes. Adv Mater. 2020;32:2003492.","journal-title":"Adv Mater"},{"key":"7074_CR19","doi-asserted-by":"publisher","first-page":"28070","DOI":"10.1021\/acsami.4c01575","volume":"16","author":"ME Janes","year":"2024","unstructured":"Janes ME, Park KS, Gottlieb AP, Curreri A, Adebowale K, Kim J, et al. Dendritic cell immune modulation via polyphenol membrane coatings. ACS Appl Mater Interfaces. 2024;16:28070\u20139.","journal-title":"ACS Appl Mater Interfaces"},{"key":"7074_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201293","volume":"9","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Kim J, Suja VC, Kapate N, Gao Y, Guo J, et al. Red blood cell anchoring enables targeted transduction and re-administration of AAV-mediated gene therapy. Adv Sci. 2022;9:2201293.","journal-title":"Adv Sci"},{"key":"7074_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124580","volume":"664","author":"C Wu","year":"2024","unstructured":"Wu C, Zhai Y, Ji J, Yang X, Ye L, Lu G, et al. Advances in tumor stroma-based targeted delivery. Int J Pharm. 2024;664:124580.","journal-title":"Int J Pharm"},{"key":"7074_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100457","volume":"17","author":"C Bae","year":"2022","unstructured":"Bae C, Kim H, Kook Y-M, Lee C, Kim C, Yang C, et al. Induction of ferroptosis using functionalized iron-based nanoparticles for anti-cancer therapy. Mater Today Bio. 2022;17:100457.","journal-title":"Mater Today Bio"},{"key":"7074_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61419-4","volume":"16","author":"S Sheng","year":"2025","unstructured":"Sheng S, Zhang Y, Jin L, Sun W, Zhu D, Mei L, et al. A ferritin-targeted biohybrid triggering ferroptosis immunotherapy via activating endogenous iron and replenishing exogenous iron simultaneously. Nat Commun. 2025;16:6045.","journal-title":"Nat Commun"},{"key":"7074_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007356","volume":"33","author":"Y Guo","year":"2021","unstructured":"Guo Y, Sun Q, Wu F-G, Dai Y, Chen X. Polyphenol-containing nanoparticles: synthesis, properties, and therapeutic delivery. Adv Mater. 2021;33:2007356.","journal-title":"Adv Mater"},{"key":"7074_CR25","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1021\/cm403903m","volume":"26","author":"MA Rahim","year":"2014","unstructured":"Rahim MA, Ejima H, Cho KL, Kempe K, M\u00fcllner M, Best JP, et al. Coordination-driven multistep assembly of metal\u2013polyphenol films and capsules. Chem Mater. 2014;26:1645\u201353.","journal-title":"Chem Mater"},{"key":"7074_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02508-2","volume":"22","author":"P Xue","year":"2024","unstructured":"Xue P, Zhuang H, Bai T, Zeng X, Deng J, Shao S, et al. Iron (II)-based metal-organic framework nanozyme for boosting tumor ferroptosis through inhibiting DNA damage repair and system Xc. J Nanobiotechnol. 2024;22:228.","journal-title":"J Nanobiotechnol"},{"key":"7074_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1039\/D3NR04733D","volume":"16","author":"J Lim","year":"2024","unstructured":"Lim J, Lee J, Boo Y, Kim WJ. A polymeric iron oxide nanocomplex loaded with sulfasalazine: an approach for inducing ferritinophagy-assisted ferroptosis for anti-cancer therapy. Nanoscale. 2024;16:742\u201351.","journal-title":"Nanoscale"},{"key":"7074_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41416-019-0611-6","volume":"121","author":"M Rouyer","year":"2019","unstructured":"Rouyer M, Oudard S, Joly F, Fizazi K, Tubach F, Jove J, et al. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. Br J Cancer. 2019;121:1001\u20138.","journal-title":"Br J Cancer"},{"key":"7074_CR29","first-page":"163","volume":"5","author":"CK Tsao","year":"2011","unstructured":"Tsao CK, Seng S, Oh WK, Galsky MD. Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer. Clin Med Insights: Oncol. 2011;5:163\u20139.","journal-title":"Clin Med Insights: Oncol"},{"key":"7074_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1208\/s12249-025-03286-2","volume":"27","author":"Y Xu","year":"2025","unstructured":"Xu Y, Kuang Y, Chen H, Zhou J, Guo B, Shu R, et al. Enhanced Efficacy and Safety: Cabazitaxel Nanodispersions as a Novel Therapeutic Platform against Prostate Cancer. AAPS PharmSciTech. 2025;27:50.","journal-title":"AAPS PharmSciTech"},{"key":"7074_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13046-025-03530-4","volume":"44","author":"L Zhang","year":"2025","unstructured":"Zhang L, Sun Q, Zheng D, Huang X, Yu Z, Lan Z, et al. PSMA-targeted theranostic nanoplatform achieves spatiotemporally precise therapy and triggers ferroptosis in prostate cancer treatment. J Exp Clin Cancer Res. 2025;44:272.","journal-title":"J Exp Clin Cancer Res"},{"key":"7074_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ccr.2018.12.015","volume":"382","author":"M Liu","year":"2019","unstructured":"Liu M, Liu B, Liu Q, Du K, Wang Z, He N. Nanomaterial-induced ferroptosis for cancer specific therapy. Coord Chem Rev. 2019;382:160\u201380.","journal-title":"Coord Chem Rev"},{"key":"7074_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-82917-3","volume":"14","author":"C Luo","year":"2024","unstructured":"Luo C, Li X, Yan H, Guo Q, Liu J, Li Y. Iron oxide nanoparticles induce ferroptosis under mild oxidative stress in vitro. Sci Rep. 2024;14:31383.","journal-title":"Sci Rep"},{"key":"7074_CR34","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1039\/D0NR08478F","volume":"13","author":"H Zheng","year":"2021","unstructured":"Zheng H, Jiang J, Xu S, Liu W, Xie Q, Cai X, et al. Nanoparticle-induced ferroptosis: detection methods, mechanisms and applications. Nanoscale. 2021;13:2266\u201385.","journal-title":"Nanoscale"},{"key":"7074_CR35","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/molecules27133970","volume":"27","author":"R Fern\u00e1ndez-Acosta","year":"2022","unstructured":"Fern\u00e1ndez-Acosta R, Iriarte-Mesa C, Alvarez-Alminaque D, Hassannia B, Wiernicki B, D\u00edaz-Garc\u00eda AM, et al. Novel Iron Oxide Nanoparticles Induce Ferroptosis in a Panel of Cancer Cell Lines. Molecules. 2022;27:3970.","journal-title":"Molecules"},{"key":"7074_CR36","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.tcb.2020.02.009","volume":"30","author":"BR Stockwell","year":"2020","unstructured":"Stockwell BR, Jiang X, Gu W. Emerging Mechanisms and Disease Relevance of Ferroptosis. Trends Cell Biol. 2020;30:478\u201390.","journal-title":"Trends Cell Biol"},{"key":"7074_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"S Yang Wan","year":"2014","unstructured":"Yang Wan S, SriRamaratnam R, Welsch Matthew E, Shimada K, Skouta R, Viswanathan Vasanthi S, et al. Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell"},{"key":"7074_CR38","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.7150\/thno.38069","volume":"10","author":"P Mi","year":"2020","unstructured":"Mi P. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics. 2020;10:4557\u201388.","journal-title":"Theranostics"},{"key":"7074_CR39","doi-asserted-by":"publisher","first-page":"27042","DOI":"10.1039\/D5NR02990B","volume":"17","author":"J Jiang","year":"2025","unstructured":"Jiang J, Jin L, Zhao Z, Gao P, Li M, Zheng X, et al. Design and application of proton gradient-based pH-responsive nanomaterials in the tumor microenvironment. Nanoscale. 2025;17:27042\u201365.","journal-title":"Nanoscale"},{"key":"7074_CR40","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.biotechadv.2013.11.009","volume":"32","author":"J Liu","year":"2014","unstructured":"Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, et al. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2014;32:693\u2013710.","journal-title":"Biotechnol Adv"},{"key":"7074_CR41","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA Weaver","year":"2014","unstructured":"Weaver BA. How Taxol\/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677\u201381.","journal-title":"Mol Biol Cell"},{"key":"7074_CR42","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"MA Jordan","year":"2004","unstructured":"Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253\u201365.","journal-title":"Nat Rev Cancer"},{"key":"7074_CR43","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"J Dixon Scott","year":"2012","unstructured":"Dixon Scott J, Lemberg Kathryn M, Lamprecht Michael R, Skouta R, Zaitsev Eleina M, Gleason Caroline E, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u201372.","journal-title":"Cell"},{"key":"7074_CR44","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714\u201326.","journal-title":"Nat Rev Cancer"},{"key":"7074_CR45","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nbt.2284","volume":"30","author":"B Al-Lazikani","year":"2012","unstructured":"Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30:679\u201392.","journal-title":"Nat Biotechnol"},{"key":"7074_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","volume":"8","author":"D Trachootham","year":"2009","unstructured":"Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8:579\u201391.","journal-title":"Nat Rev Drug Discov"},{"key":"7074_CR47","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931\u201347.","journal-title":"Nat Rev Drug Discov"},{"key":"7074_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551:247\u201350.","journal-title":"Nature"}],"container-title":["Journal of Materials Science: Materials in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10856-026-07074-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-026-07074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10856-026-07074-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:02:57Z","timestamp":1784044977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10856-026-07074-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7074"],"URL":"https:\/\/doi.org\/10.1007\/s10856-026-07074-7","relation":{},"ISSN":["1573-4838"],"issn-type":[{"value":"1573-4838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}],"article-number":"86"}}